Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

× No keyword cloud information.

39 in total

1. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

Authors: Hiroshi Hirose; Toshihide Kawai; Yukihiro Yamamoto; Matsuo Taniyama; Motowo Tomita; Koichi Matsubara; Yasunori Okazaki; Tatsuya Ishii; Yuko Oguma; Izumi Takei; Takao Saruta
Journal: Metabolism Date: 2002-03 Impact factor: 8.694

2. Pioglitazone-associated fulminant hepatic failure.

Authors: Michael P Chase; Joseph C Yarze
Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864

Review 3. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

Authors: J Kohlroser; J Mathai; J Reichheld; B F Banner; H L Bonkovsky
Journal: Am J Gastroenterol Date: 2000-01 Impact factor: 10.864

4. Hepatic dysfunction associated with troglitazone.

Authors: P B Watkins; R W Whitcomb
Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245

5. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

Authors: Louis D May; Jay H Lefkowitch; Michael T Kram; David E Rubin
Journal: Ann Intern Med Date: 2002-03-19 Impact factor: 25.391

Review 6. Pioglitazone: a review of Japanese clinical studies.

Authors: S Baba
Journal: Curr Med Res Opin Date: 2001 Impact factor: 2.580

7. Liver biopsy in psoriasis. A controlled study.

Authors: H Zachariae; H Sogaard
Journal: Dermatologica Date: 1973

8. Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.

Authors:
Journal: Expert Opin Investig Drugs Date: 1999-11 Impact factor: 6.206

Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.

1. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

2. Pioglitazone-associated fulminant hepatic failure.

Review 3. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

4. Hepatic dysfunction associated with troglitazone.

5. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

Review 6. Pioglitazone: a review of Japanese clinical studies.

7. Liver biopsy in psoriasis. A controlled study.

8. Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.

Review 9. Diabetes mellitus, obesity, and hepatic steatosis.

10. Ursodeoxycholate alleviates alcoholic fatty liver damage in rats.

1. Nonalcoholic Steatohepatitis.

Review 2. The Role of Transcription Factor PPAR-γ in the Pathogenesis of Psoriasis, Skin Cells, and Immune Cells.

Review 3. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.